Assenagon Asset Management S.A. Invests $9.16 Million in Fulcrum Therapeutics, Inc. $FULC

Assenagon Asset Management S.A. bought a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,193,873 shares of the company’s stock, valued at approximately $9,157,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Fulcrum Therapeutics during the 4th quarter valued at $30,000. Meeder Asset Management Inc. bought a new stake in Fulcrum Therapeutics in the 4th quarter worth $39,000. Quarry LP purchased a new position in shares of Fulcrum Therapeutics in the third quarter valued at about $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at about $75,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at about $100,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $3.80 on Monday. Fulcrum Therapeutics, Inc. has a 12 month low of $2.83 and a 12 month high of $15.74. The firm has a market capitalization of $253.19 million, a PE ratio of -3.30 and a beta of 2.93. The firm has a fifty day simple moving average of $5.74 and a two-hundred day simple moving average of $8.33.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, April 27th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. On average, sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on FULC. Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Tuesday, June 2nd. Leerink Partners downgraded Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target on the stock. in a report on Tuesday, June 2nd. Piper Sandler lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Tuesday, June 2nd. Cantor Fitzgerald cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Finally, Jefferies Financial Group set a $4.00 price objective on Fulcrum Therapeutics in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.